Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
